Pharma Dynamics’ founder, Paul Anley, has resigned as Chief Executive Officer and has named industry-veteran Erik Roos as the company’s new CEO.
Anley, who started Pharma Dynamics in 2001, has driven the company’s meteoric rise to national recognition and prominence. Pharma Dynamics is now SA’s biggest distributor of cardiovascular medicine and ranks as the third largest generic pharmaceutical company in the country.
Following the full purchase of Pharma Dynamics in April 2015 by the Lupin Group, India’s third largest pharmaceutical company by total sales, Anley will step down as CEO at the end of March 2016, but will remain a non-executive Director.
Erik Roos, former CEO of Mylan South Africa, will take over the reigns as CEO of Pharma Dynamics with effect from 1 April 2016.
Commenting on the announcement, Anley says Pharma Dynamics is ideally positioned to continue the sales momentum into the next phase of its growth.
“The company has an experienced management team, an extensive and strong sales force, and an enviable brand image and corporate reputation. This, combined with what could be the largest product pipeline in the industry, will ensure its continued success,” says Anley.
Roos’ vision for Pharma Dynamics is to sustain success and remain the fastest growing generic pharmaceutical company in SA by identifying unique future product portfolios to bolster established lines, tightening distribution and logistics in the face of exchange rate challenges and investigating the feasibility of establishing local manufacturing and packaging facilities.
He aims to break into additional therapeutic areas, such as oncology and biosimilars to boost Pharma Dynamics’ already strong position in the cardiovascular, central nervous system and over-the-counter categories.
The company is also well established in Namibia and has successfully registered various dossiers in the Southern African region.
“I am looking forward to shaping the future of our company together with an excellent local and global team. We have strong brands and technologies, leading positions in many healthcare classes in SA and with Lupin around the world. Building on this foundation, together, we will successfully lead Pharma Dynamics into the future,” concludes Roos.